Delivery Order SPE2DB25D3109-SPE2DB25FPKUS
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $8,168.32 to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials. This is a firm fixed price delivery order with an ultimate completion date of July 28, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor...
- The Defense Logistics Agency awarded a delivery order valued at $1,661.77 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. The contract was awarded on July 23, 2025, with an ultimate completion date of July 24, 2025, and represents a firm fixed-price, non-set-aside competitive award. The place of performance is listed as Conshohocken, Pennsylvania, which is the company's corporate headquarters location. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $1,278.14 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 ml) in 3 ml vials. This is a firm fixed price delivery order with an ultimate completion date of September 22, 2025, and was awarded competitively with no set-aside designation. The work will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's Indefinite Delivery...
- The Defense Logistics Agency awarded a $44,381.09 delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials, with completion targeted for August 12, 2025. This competitive, non-set-aside award reflects firm fixed pricing and represents a single delivery order under AmerisourceBergen's existing contract vehicle with DLA. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $1,004.33 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 ml) in 3 ml vials. This competitive award, issued on July 24, 2025, with an ultimate completion date of July 25, 2025, represents a firm fixed-price transaction with no set-aside designation. The order is being fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, the company's corporate headquarters and a major...
- The Defense Logistics Agency awarded a delivery order valued at $1,580.37 to AmerisourceBergen Drug Corp for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials. This competitive award, issued on August 11, 2025, with a completion date of August 12, 2025, represents a firm fixed price delivery order with no set-aside designation. The pharmaceutical product will be delivered to the Place of Performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a $13,451.77 delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) in 3 ml vials. This competitively awarded, firm fixed price contract has a completion date of July 31, 2025, and will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX),...
- The Defense Logistics Agency awarded a $31,772.81 delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml vials, with an ultimate completion date of July 17, 2025. This competitive award, issued on July 16, 2025, carries a firm fixed price and involves no set-aside designation. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company maintains its primary distribution and pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order valued at $45,468.54 to AmerisourceBergen Drug Corp for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3ml vials, with an ultimate completion date of August 13, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $3,799.81 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. This is a firm fixed price delivery order with no set-aside designation, competitively awarded and scheduled for completion by August 5, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location. The delivery order...
- SPE2DB25D3109Indefinite Delivery Contract
- SPE2DB25D3109-SPE2DB25FPKUSDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,804.40 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 ml) in 3 ml vials. The contract is a firm fixed price delivery order issued on July 18, 2025, with an ultimate completion date of July 21, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. No set-aside designation was used for this competitive award, allowing AmerisourceBergen to compete directly against other qualified vendors in the federal marketplace. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which carries a potential value of $999,999,999.00 through December 2026. The Ozempic order supports the Defense Health Agency's pharmaceutical supply requirements for military healthcare programs. AmerisourceBergen's comprehensive IDC serves as a global pharmaceutical support vehicle enabling the delivery of a broad range of brand-name and generic medications, vaccines, and medical supplies to military and federal healthcare systems worldwide. The company's extensive federal contract portfolio demonstrates its capability to fulfill complex medical procurement requirements through open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.8k | 7/18/25 |